$8.15 Million in Sales Expected for Novavax, Inc. (NVAX) This Quarter
Analysts expect that Novavax, Inc. (NASDAQ:NVAX) will announce sales of $8.15 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Novavax’s earnings, with estimates ranging from $6.00 million to $10.30 million. Novavax posted sales of $5.40 million in the same quarter last year, which suggests a positive year-over-year growth rate of 50.9%. The company is scheduled to issue its next earnings results on Monday, February 26th.
On average, analysts expect that Novavax will report full-year sales of $8.15 million for the current fiscal year, with estimates ranging from $26.76 million to $31.00 million. For the next financial year, analysts forecast that the company will report sales of $33.78 million per share, with estimates ranging from $27.50 million to $42.50 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Novavax.
Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.01. The firm had revenue of $8.35 million during the quarter, compared to the consensus estimate of $6.42 million. Novavax had a negative net margin of 726.35% and a negative return on equity of 787.38%. The business’s revenue for the quarter was up 158.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.24) EPS.
Novavax (NVAX) traded down $0.05 during midday trading on Monday, reaching $1.38. 5,569,973 shares of the company’s stock were exchanged, compared to its average volume of 5,921,584. The company has a quick ratio of 3.31, a current ratio of 3.31 and a debt-to-equity ratio of -4.28. Novavax has a 52-week low of $0.73 and a 52-week high of $1.78.
In other news, insider Stanley C. Erck bought 100,000 shares of the company’s stock in a transaction dated Thursday, November 9th. The stock was bought at an average cost of $1.13 per share, for a total transaction of $113,000.00. Following the transaction, the insider now owns 228,279 shares of the company’s stock, valued at $257,955.27. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.00% of the stock is currently owned by insiders.
Hedge funds have recently added to or reduced their stakes in the stock. Raymond James Financial Services Advisors Inc. increased its position in Novavax by 49.8% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 89,697 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 29,800 shares in the last quarter. Profund Advisors LLC increased its position in Novavax by 0.4% during the 2nd quarter. Profund Advisors LLC now owns 120,775 shares of the biopharmaceutical company’s stock worth $139,000 after purchasing an additional 455 shares in the last quarter. Voya Investment Management LLC increased its position in Novavax by 18.6% during the 2nd quarter. Voya Investment Management LLC now owns 138,270 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 21,639 shares in the last quarter. Brown Advisory Inc. increased its position in Novavax by 74.8% during the 3rd quarter. Brown Advisory Inc. now owns 162,700 shares of the biopharmaceutical company’s stock worth $185,000 after purchasing an additional 69,600 shares in the last quarter. Finally, State of Wisconsin Investment Board acquired a new position in Novavax during the 2nd quarter worth approximately $230,000. Institutional investors and hedge funds own 36.80% of the company’s stock.
Novavax Company Profile
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.